Hypoxia-Inducible Factors in Cancer.
Hypoxia-Inducible Factors in Cancer.
复制标题
DOI：
10.1158/0008-5472.can-21-3780
复制
发表时间：
2022-01-15
期刊：
影响因子：
11.2
通讯作者：
Simon, M. Celeste
中科院分区：
文献类型：
--
作者：
Kim, Laura C.;Simon, M. Celeste
低氧浓度（缺氧）对地球上的大多数物种都是有害的；因此，细胞已经进化出适应性，使它们能够承受短暂的缺氧。与其他生存途径一样，癌细胞也采用了这些机制来满足恶劣的肿瘤微环境中快速生长和增殖的代谢需求。研究最充分的氧反应途径涉及缺氧诱导因子 (HIF) 及其受 von Hippel-Lindau 蛋白 (pVHL) 和脯氨酰羟化酶 (PHD1-3) 的调节。 Chung 及其同事的这项研究于 1999 年发表在《癌症研究》杂志上，首次表明 HIF1α 在几种癌症类型和转移瘤中表达增加，表明 HIF 在疾病进展中发挥作用。自发表以来，对肿瘤缺氧反应的理解已经取得了重大进展，并且正在努力将该途径作为癌症患者的治疗策略。
Low oxygen concentrations (hypoxia) are detrimental to most species on Earth; thus, cells have evolved with adaptations allowing them to withstand transient hypoxia. As with other survival pathways, cancer cells have co-opted these mechanisms to keep up with the metabolic demands of rapid growth and proliferation in harsh tumor microenvironments. The most well-studied oxygen response pathway involves hypoxia-inducible factors (HIFs) and their regulation by the von Hippel-Lindau protein (pVHL) and the prolyl hydroxylases (PHD1–3). This study from Zhong and colleagues, published in Cancer Research in 1999, was the first to show increased HIF1α expression in several cancer types and in metastases, suggesting a role for HIFs in disease progression. Since publication, significant progress has been made in the understanding of tumor hypoxia responses and efforts to target this pathway as a therapeutic strategy for cancer patients are underway.